Use of Trap Protein Per se as an Active Ingredient for the Manufacture of a Medicament for the Treatment of Staphylococcus Aureus Infection

• US 20090305975A1
• Filed: 04/16/2007
• Published: 12/10/2009
• Est. Priority Date: 04/17/2006
• Status: Abandoned Application

• Current Assignee: Hainan GT-Unipul Pharmaceutical Co., Ltd.
• Original Assignee: Hainan GT-Unipul Pharmaceutical Co., Ltd.
• Inventors: Liu, Chuan, Dong, Jie, Shen, Beifen, Shao, Ningsheng, Gao, Yaping, Liu, Yu, Yang, Guang, Li, Shaohua, Fan, Ming
• Application Number:
  US12/226,491
• Publication Number:
  US 20090305975A1
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61K 38/164 from bacteria
• CPC Class Codes: A61P 31/04 Antibacterial agents

Abstract

Disclosed herein is the use of TRAP per se as an active ingredient for the manufacture of a medicament for the treatment of Staphylococcus aureus infection. An exogenous TRAP (native TRAP or recombinant TRAP) per se can effectively inhibit the production of Staphylococcus aureus exotoxins, thereby reducing the pathogenicity of Staphylococcus aureus. In addition, a medicament including TRAP also stimulates the production of corresponding antibodies in human body at the time when it is used to treat Staphylococcus aureus infections, and these antibodies can further inhibit the production of Staphylococcus aureus exotoxins. Such double actions increase the effects of medicament and provide a novel medicament action mode. Moreover, since TRAP functions merely to the toxicity of bacteria but does not affect the growth of bacteria, it cannot make bacteria readily develop drug resistance, and also effective to drug resistant Staphylococcus aureus. Moreover, no homologous sequence of the TRAP proteins is found in human genome, so that the medicaments of TRAP cannot cause human immunologic diseases.

Claims

1. Use of TRAP per se as an active ingredient in the manufacture of a medicament for the treatment of Staphylococcus aureus infections.

2. The use according to claim 1, wherein said TRAP is selected from the group consisting of native TRAP, recombinant TRAP, intact TRAP, fusion proteins comprising TRAP, chemical modifiers of TRAP, or biologically active fragments thereof.

3. The use according to claim 1, wherein said TRAP is from Staphylococci.

4. The use according to claim 3, wherein said TRAP is from Staphylococcus aureus.

5. The use according to claim 1, wherein said TRAP has a sequence identity of at least 70% to the sequence as shown in SEQ ID NO:

2 or 4.

6. The use according to claim 1, wherein said medicament is a pharmaceutical composition comprising TRPA and optionally, a pharmaceutically acceptable carrier.

7. The use according to claim 1, wherein said medicament is present in a dosage form comprising:

sterile aqueous or non-aqueous injectable solutions;

dispersions;

suspensions or emulsions;

sterile powders and freeze-dried powders for parenteral administration;

hard or soft capsules;

tablets;

troches;

sugar-coated pills;

pills;

lozenges;

powders and granules for oral administration;

emulsions;

aqueous or oily suspensions;

syrups and elixirs;

suppositories;

aerosols;

ointments;

creams;

gelatins;

inhalants;

or bandages for skin and implants for external use.

8. A method for treating Staphylococcus aureus infections, comprising administrating a therapeutically effective amount of TRAP to a subject suffering from Staphylococcus aureus infections.

9. The method according to claim 8, wherein said TRAP is selected from the group consisting of native TRAP, recombinant TRAP, intact TRAP, fusion proteins comprising TRAP, chemical modifiers of TRAP, or biologically active fragments thereof.

10. The method according to claim 8, wherein said TRAP protein has a sequence identity of at least 70% to the sequence as shown in SEQ ID NO:

2 or 4.